Drug intelligence / Profile preview

Xinnaojing Pian

Development stage: Unknown
Lead developer: Tianjin Pharmaceutical Da Ren Tang Group
Modality: Small Molecules
Administration: Oral

Overview

Xinnaojing Pian is a marketed Traditional Chinese Medicine (TCM) oral tablet developed and manufactured by Tianjin Pharmaceutical Da Ren Tang. It is primarily indicated for the treatment of cardiovascular and cerebrovascular conditions. In the context of TCM theory, the formulation is designed to clear heat, detoxify, and calm the nerves (settle fright). It is clinically used to alleviate symptoms such as dizziness, restlessness, slurred speech, and complications associated with arteriosclerosis. As a multi-herb formulation, its therapeutic profile is attributed to the synergistic effects of its constituent natural ingredients rather than a single molecular target.

Brand names: 心脑静片
Other names: Xinnaojing tablets

Beyond the preview

Go deeper on Xinnaojing Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinnaojing Pian.

Explore the full profile